Evidence map›Paper›PMID 37949667›Full record

Observational studyNeurology(R) neuroimmunology & neuroinflammation2024

Clinical Determinants of Longitudinal Disability in LGI-1-IgG Autoimmune Encephalitis.

Albert Aboseif, Yadi Li, Moein Amin, Brittany Lapin, Alex Milinovich, Justin R Abbatemarco, Jeffrey A Cohen, Vineet Punia, Alex D Rae-Grant, Rachel Galioto and 1 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurology(R) neuroimmunology & neuroinflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Evaluation of the clinical assessment scale for autoimmune encephalitis (CASE) in a retrospective cohort and a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  3. Observational
  4. Observational
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Autoimmune encephalitis.Nature reviews. Disease primers · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Clonal hematopoiesis in LGI1-antibody encephalitis.Annals of clinical and translational neurology · 2024
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Albert AboseifFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.ORCID 0000-0001-5053-8544
Yadi LiFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.
Moein AminFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.ORCID 0000-0002-9587-0644
Brittany LapinFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.
Alex MilinovichFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.
Justin R AbbatemarcoFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.ORCID 0000-0003-1668-4753
Jeffrey A CohenFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.ORCID 0000-0001-9245-9772
Vineet PuniaFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.ORCID 0000-0002-0552-6736
Alex D Rae-GrantFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.ORCID 0000-0003-3027-9703
Rachel GaliotoFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH.
Amy KunchokFrom the Department of Neurology (A.A.), Neurological Institute; Department of Quantitative Health Sciences (Y.L., B.L., A.M.), Lerner Research Institute; Center for Outcomes Research and Evaluation (Y.L., B.L.); Mellen Center for Multiple Sclerosis Treatment and Research (M.A., J.R.A., J.A.C., A.K.); Epilepsy Center (V.P.), Neurologic Institute, Cleveland Clinic; and Cleveland Clinic Lerner College of Medicine (A.D.R.-G.), OH. kunchoa@ccf.org.ORCID 0000-0002-8387-6491
Cleveland Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesLongitudinal outcome studies in leucine-rich glioma inactivated-1 (LGI-1) immunoglobulin G (IgG) autoimmune encephalitis (AE) are needed to inform clinical management and prognostication. This study aims to evaluate longitudinal predictors of disability and disease severity in LGI-1-IgG AE.

methodsThis retrospective observational study of patients with LGI-1-IgG AE was conducted between 2013-2022. Disability and disease severity were defined by scores on the modified Rankin Scale (mRS) and the clinical assessment scale in AE (CASE), respectively. Demographic variables, clinical/paraclinical data, brain MRI, and Montreal Cognitive Assessment (MOCA) scores were examined as predictors of mRS and CASE scores in logistic and linear regression models, respectively.

resultsThirty patients (60% male, median age = 68.5; interquartile range (IQR) = 63.0-75.0) were included, with a median follow-up time of 19.1 months (IQR = 5.3-47.1) The majority developed seizures (29, [97%]) and/or cognitive impairment (30, [100%]) and received acute (27, [90%]) and maintenance (23 [77%]) immunotherapy. The median initial MOCA was 23/30 (IQR = 21.0-25.0). Baseline mRS (median = 2.0, IQR = 2.0-3.0) and CASE (mean = 4.3, SD = 3.7) correlated with one another (r = 0.58, DISCUSSION: Overall, there was a high degree of correlation between mRS and CASE scores in patients with LGI-1-IgG AE, with both scores improving significantly after 12 months. Memory dysfunction and psychiatric disturbance were the most prevalent longitudinal symptoms. Cognitive impairment and temporal lobe T2 hyperintensity at baseline were both associated with greater disability at long-term follow-up, underscoring these as important determinants of disability outcomes in LGI-1-IgG AE.

Indexed as

Autoimmune Diseases of the Nervous SystemEncephalitisAgedFemaleHashimoto DiseaseHumansImmunoglobulin GLeucineMaleImmunoglobulin GLeucine

Identifiers

PMID37949667
PMCPMC10691218
OpenAlexW4388563357

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.